Literature DB >> 19380455

Acute hyperinsulinemia decreases plasma osteoprotegerin with diminished effect in type 2 diabetes and obesity.

Gitte Maria Jørgensen1, Birgitte Vind, Mads Nybo, Lars Melholt Rasmussen, Kurt Højlund.   

Abstract

OBJECTIVE: Osteoprotegerin (OPG) is a soluble tumour necrosis factor-receptor-like molecule present in connective tissues, especially bone and vasculature. It is known to accumulate in the arterial wall in diabetes. As its synthesis in vascular cells is decreased by insulin, we wanted to elucidate the acute effects of insulin on plasma OPG concentrations in individuals with type 2 diabetes and obese individuals compared with lean controls.
DESIGN: The study population consisted of ten type 2 diabetic, ten obese subjects, and ten lean subjects with no family history of diabetes.
METHODS: All subjects underwent a 4-h euglycemic-hyperinsulinemic clamp. Plasma OPG, insulin, lactate, HbA1c, cholesterol, triglycerides, free fatty acids (FFA), and glucose disposal rate were measured before and at the end of the clamp.
RESULTS: Baseline OPG concentrations did not differ significantly between groups. Insulin infusion decreased plasma OPG concentrations in all groups (P<0.01); however, the fall in OPG was 50% less in obese and type 2 diabetic individuals (P=0.007). Baseline OPG correlated with fasting insulin, baseline lactate, and low density lipoprotein cholesterol in the diabetic group, and with baseline FFA in the lean group. The relative change of OPG in response to insulin correlated inversely with HbA1c and baseline FFA in the lean group.
CONCLUSIONS: Acute hyperinsulinemia decreases plasma OPG, but with diminished effect in individuals with type 2 diabetes and obesity. Increased levels of OPG in arteries and plasma in diabetes together with the capability of plasma OPG as a cardiovascular risk predictor may be related to the described effects of insulin.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19380455     DOI: 10.1530/EJE-09-0141

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  11 in total

1.  Increased serum concentrations of persistent organic pollutants among prediabetic individuals: potential role of altered substrate oxidation patterns.

Authors:  Kristine Færch; Kurt Højlund; Birgitte F Vind; Allan Vaag; Christine Dalgård; Flemming Nielsen; Philippe Grandjean
Journal:  J Clin Endocrinol Metab       Date:  2012-06-26       Impact factor: 5.958

Review 2.  Inflammation as death or life signal in diabetic fracture healing.

Authors:  Tamás Roszer
Journal:  Inflamm Res       Date:  2010-09-16       Impact factor: 4.575

3.  Hyperglycaemia normalises insulin action on glucose metabolism but not the impaired activation of AKT and glycogen synthase in the skeletal muscle of patients with type 2 diabetes.

Authors:  B F Vind; J B Birk; S G Vienberg; B Andersen; H Beck-Nielsen; J F P Wojtaszewski; K Højlund
Journal:  Diabetologia       Date:  2012-02-10       Impact factor: 10.122

4.  A Signature of Exaggerated Adipose Tissue Dysfunction in Type 2 Diabetes Is Linked to Low Plasma Adiponectin and Increased Transcriptional Activation of Proteasomal Degradation in Muscle.

Authors:  Rugivan Sabaratnam; Vibe Skov; Søren K Paulsen; Stine Juhl; Rikke Kruse; Thea Hansen; Cecilie Halkier; Jonas M Kristensen; Birgitte F Vind; Bjørn Richelsen; Steen Knudsen; Jesper Dahlgaard; Henning Beck-Nielsen; Torben A Kruse; Kurt Højlund
Journal:  Cells       Date:  2022-06-23       Impact factor: 7.666

5.  Treatment with recombinant tumor necrosis factor-related apoptosis-inducing ligand alleviates the severity of streptozotocin-induced diabetes.

Authors:  Giorgio Zauli; Barbara Toffoli; Maria Grazia di Iasio; Claudio Celeghini; Bruno Fabris; Paola Secchiero
Journal:  Diabetes       Date:  2010-02-25       Impact factor: 9.461

Review 6.  Osteoprotegerin in Cardiometabolic Disorders.

Authors:  C Pérez de Ciriza; A Lawrie; N Varo
Journal:  Int J Endocrinol       Date:  2015-05-11       Impact factor: 3.257

7.  Association of Osteoprotegerin with Obesity, Insulin Resistance and Non-Alcoholic Fatty Liver Disease in Children.

Authors:  Meltem Erol; Ozlem Bostan Gayret; Hikmet Tekin Nacaroglu; Ozgul Yigit; Oguzhan Zengi; Mehmet Salih Akkurt; Mehmet Tasdemir
Journal:  Iran Red Crescent Med J       Date:  2016-11-01       Impact factor: 0.611

Review 8.  The Role of Osteoprotegerin as a Cardioprotective Versus Reactive Inflammatory Marker: the Chicken or the Egg Paradox

Authors:  Flora Özkalaycı; Öykü Gülmez; Betül Uğur-Altun; Seithikurippu Ratnas Pandi-Perumal; Armağan Altun
Journal:  Balkan Med J       Date:  2018-04-24       Impact factor: 2.021

9.  SNP rs2073618 of the osteoprotegerin gene is associated with diabetic retinopathy in Slovenian patients with type 2 diabetes.

Authors:  Sara Mankoč Ramuš; Tina Kumše; Mojca Globočnik Petrovič; Daniel Petrovič; Ines Cilenšek
Journal:  Biomed Res Int       Date:  2013-10-20       Impact factor: 3.411

Review 10.  Osteoprotegerin (OPG) as a biomarker for diabetic cardiovascular complications.

Authors:  Mette Bjerre
Journal:  Springerplus       Date:  2013-12-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.